Biotech RadarJobs updated

COMPANY

Bristol-Myers Squibb

HQ: Princeton, NJ source · bms.com ↗

FDA-approved therapeutic company FDA-cleared device company Clinical Phase 3

732 open jobs · last seen Oct 22, 2026 · 60 sources

Bristol Myers Squibb is a global biopharmaceutical company. From company website Source · Oct 12, 2026

Keywords: biopharmaceutical Non-Small Cell Lung Cancer Alzheimer's Disease Schizophrenia Myelodysplastic Syndromes Obstructive Hypertrophic Cardiomyopathy Relapsed or Refractory T-cell Lymphomas Myelofibrosis Advanced Breast Cancer Advanced Ovarian Cancer Juvenile Psoriatic Arthritis Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Metastatic Non-Small Cell Lung Cancer (NSCLC) Psoriasis Lower-risk Myelodysplastic Syndromes (TD LR-MDS) Acute Myeloid Leukemia Rheumatoid Arthritis Multiple Myeloma Renal Cell Carcinoma Myelodysplastic Syndrome Chronic Kidney Failure Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Hypertrophic Cardiomyopathy Irritability Associated With Autism Spectrum Disorder Alzheimer Disease Agitation Psoriatic Arthritis Bipolar Disorder Type I With Mania or Mania With Mixed Features Relapsed or Refractory Multiple Myeloma Ulcerative Colitis Small Cell Lung Carcinoma Advanced Renal Cell Carcinoma (RCC) Metastatic Non-small Cell Lung Cancer With MTAP Deletion Untreated, Unresectable, or Metastatic Colorectal Cancer Lung Cancer Breast Cancer Hepatocellular Carcinoma

Location: Princeton, NJ · source · Oct 14, 2026

Profile checked Oct 10, 2026

732+7 patient-care hiddenOpen jobs1,560Trials (company is sponsor)19FDA records (2 yrs)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Cybersecurity Specialist II - Application SecurityHyderabad - TS - INOct 22, 2026Oct 13, 2026
Clinical Trial Results ManagerHyderabad - TS - INOct 22, 2026Oct 22, 2026
Clinical Trial Registration Manager IIHyderabad - TS - INOct 22, 2026Oct 22, 2026
Risk Analyst IIHyderabad - TS - INOct 22, 2026Oct 22, 2026
Speciality Care Advisor (Field based in Delhi)Field - India - INOct 22, 2026Oct 22, 2026

See all 732 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Trial start Phase 1: Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants. source ↗
  2. Trial start —: Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusi source ↗
  3. Board tracked Radar started tracking this company’s job board (739 open jobs at last check). source ↗
  4. Trial start Phase 3: A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder source ↗
  5. FDA FDA New indication / efficacy supplement: CAMZYOS (mavacamten) — NDA214998/13, Sep 30, 2026. Applicant at approval: Bristol-Myers Squibb Company. source ↗
  6. Trial start —: Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy source ↗
  7. Trial start Phase 2: A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment source ↗
  8. Trial start Phase 3: Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-smal source ↗
  9. Trial start Phase 1: A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Functi source ↗
  10. Trial start Phase 1: A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants source ↗
  11. Trial start Phase 1: A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Pa source ↗
  12. FDA FDA New drug/biologic (novel): ZENBEXUS (iberdomide hydrochloride) — NDA221075, Aug 13, 2026. Applicant at approval: Bristol-Myers Squibb Company. Accelerated approval. source ↗
  13. Trial start —: Asia Myelodysplastic Syndrome (MDS) Registry source ↗
  14. Trial start Phase 2: A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) source ↗
  15. Trial start —: First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain source ↗
  16. Trial start 1: A Phase 1 Study of Navlimetostat Tablet Formulations source ↗
  17. FDA FDA New indication / efficacy supplement: ONUREG (azacitidine) — NDA214120/3, Apr 9, 2026. Applicant at approval: Bristol-Myers Squibb Company. source ↗
  18. Trial start Phase 1/Phase 2: A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC source ↗
  19. FDA FDA New indication / efficacy supplement: OPDIVO (nivolumab) — BLA125554/135, Mar 20, 2026. Applicant at approval: Bristol-Myers Squibb Company. source ↗
  20. Trial start Phase 3: A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) source ↗
  21. Trial start Phase 1/Phase 2: A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma source ↗
  22. Trial start Phase 2/Phase 3: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated A source ↗
  23. Trial start Phase 3: A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) source ↗
  24. FDA FDA New indication / efficacy supplement: SOTYKTU (deucravacitinib) — NDA214958/2, Mar 6, 2026. Applicant at approval: Bristol Myers Squibb Company. source ↗
  25. Trial start Phase 1: A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis source ↗

Showing 25 of 70 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 732

7 patient-care jobs hidden (phlebotomy, plasma-center, nursing and similar care roles; 739 open jobs in total).

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Cybersecurity Specialist II - Application SecurityHyderabad - TS - INOct 22, 2026Oct 13, 2026Not stated
Clinical Trial Results ManagerHyderabad - TS - INOct 22, 2026Oct 22, 2026Not stated
Clinical Trial Registration Manager IIHyderabad - TS - INOct 22, 2026Oct 22, 2026Not stated
Risk Analyst IIHyderabad - TS - INOct 22, 2026Oct 22, 2026Not stated
Speciality Care Advisor (Field based in Delhi)Field - India - INOct 22, 2026Oct 22, 2026Not stated
EMEA Payroll AnalystWarsaw - PLOct 22, 2026Oct 22, 2026Not stated
Senior Manager I, Advanced Capabilities COEHyderabad - TS - INOct 22, 2026Oct 22, 2026Not stated
Senior Analyst (Business Analyst II)Hyderabad - TS - INOct 22, 2026Oct 22, 2026Not stated
Director, Biostatistics3 locations, including US, NJ, Giralda, MadisonOct 22, 2026Oct 22, 2026Not stated
Specialist, APAC Site Accounts, Scheduling & Cell LogisticsOtemachi-JPOct 22, 2026Oct 22, 2026Not stated
Senior Manager, Health Economics & Outcomes Research (HEOR)Otemachi-JPOct 22, 2026Oct 22, 2026Not stated
Manager, Technical Lead, Sterile Drug Product (Manufacturing)Cruiserath - IEOct 21, 2026Oct 7, 2026Senior
Associate, QC Analytical, Cell TherapyDevens - MA - USOct 21, 2026Oct 7, 2026Not stated
Sr. Manager, Marketing and Commercialization Capability Development, Commercialization Learning Japancialization Learning JapanOtemachi-JPOct 21, 2026Oct 7, 2026Senior
Executive Director, Research – Integrative Sciences — Cardiovascular2 locations, including US, MA, Cambridge CrossingOct 21, 2026Oct 7, 2026Executive
Sr. Medical Information Communication Specialist, IONanjing - CNOct 21, 2026Oct 7, 2026Mid
Director, Drug Development AI Nexus Decision Integration Lead4 locations, including US, NJ, PrincetonOct 21, 2026Oct 7, 2026Senior
Senior Therapeutic Area Specialist, Cardiovascular Community - Lafayette, IN/Northwest Indiana2 locations, including US, IN, LafayetteOct 21, 2026Oct 22, 2026Not stated
Executive Director, Chief of Staff, Global Development Operations2 locations, including CH, BoudryOct 21, 2026Oct 22, 2026Not stated
Director - US Field HEOR ScientistField - United States - USOct 21, 2026Oct 22, 2026Not stated
Associate Director, Customer Insights & Engagement, Lung CancerPrinceton - NJ - USOct 21, 2026Oct 22, 2026Not stated
Associate Director, Aseptic Facility and Utility Design7 locations, including US, NJ, New BrunswickOct 21, 2026Oct 22, 2026Not stated
Associate Director, Clinical PharmacologyPrinceton - NJ - USOct 21, 2026Oct 22, 2026Not stated
Senior Manager Biospecimen Lead2 locations, including US, NJ, PrincetonOct 21, 2026Oct 22, 2026Not stated
ElectricianDevens - MA - USOct 21, 2026Oct 22, 2026Not stated
Senior Specialist, Field Quality QA OperationsDevens - MA - USOct 21, 2026Oct 22, 2026Not stated
Associate ScientistSeattle, WAOct 21, 2026Oct 22, 2026Not stated
Associate Director, Portfolio ConsolidationPrinceton - NJ - USOct 21, 2026Oct 22, 2026Not stated
Senior Scientist, Gene Delivery and Editing Process DevelopmentSeattle, WAOct 21, 2026Oct 22, 2026Not stated
Director, ASAT Critical Reagent Operations3 locations, including US, MA, DevensOct 21, 2026Oct 22, 2026Not stated
International Therapeutic Area Head Immunology/Cardiovascular8 locations, including CH, BoudryOct 21, 2026Oct 22, 2026Not stated
Director, Global Clinical Trial Physician2 locations, including GB, UxbridgeOct 21, 2026Oct 22, 2026Not stated
Senior Technician, Clinical Supply Warehouse & Logistics OperationsMoreton - GBOct 21, 2026Oct 22, 2026Not stated
Manager, Operations Supply Planner2 locations, including Dublin, EXMFGOct 21, 2026Oct 22, 2026Not stated
Manager, Quality Engineering, Change Control/Document ReviewMadison - Giralda - NJ - USOct 21, 2026Oct 22, 2026Not stated
Senior Manager, QA Engineering (Equipment/Lab Methods/Utilities/Facilities)Madison - Giralda - NJ - USOct 21, 2026Oct 22, 2026Not stated
Senior Manufacturing Associate, Cell Therapy in Devens, MADevens - MA - USOct 21, 2026Oct 22, 2026Not stated
Senior Manufacturing Associate, Cell Therapy in Devens, MADevens - MA - USOct 21, 2026Oct 22, 2026Not stated
Drug Product Associate, Sterile Drug ProductCruiserath - IEOct 21, 2026Oct 22, 2026Not stated
Senior Specialist, Submission ManagementWarsaw - PLOct 21, 2026Oct 22, 2026Not stated
Manager, Submission ManagementWarsaw - PLOct 21, 2026Oct 22, 2026Not stated
Therapeutic Area Specialist, Hematology & Oncology (m/f/d) - Gebiet 10303: Heidelberg, Mannheim, Heilbronn, Freiburg4 locations, including DE, Germany, FieldOct 21, 2026Oct 22, 2026Not stated
ScientistNew Brunswick - NJ - USOct 21, 2026Oct 22, 2026Not stated
Senior Specialist, QCAS InstrumentationCruiserath - IEOct 21, 2026Oct 22, 2026Not stated
Senior Manager, Regulatory Sciences (m/w/d)Munich - DEOct 21, 2026Oct 22, 2026Not stated
Therapeutic Area Specialist ImmunologyField - Poland - PLOct 21, 2026Oct 22, 2026Not stated
Senior Manager, Content Strategy & EnablementOtemachi-JPOct 21, 2026Oct 22, 2026Not stated
Global Trial Acceleration AssociateHyderabad - TS - INOct 21, 2026Oct 22, 2026Not stated
IO Medical Information Communication SpecialistJinan - CNOct 21, 2026Oct 22, 2026Not stated
2027 Summer Intern Real EstatePrinceton - NJ - USOct 20, 2026Oct 7, 2026Entry

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 732 jobs →

Clinical trials (lead sponsor) Showing 50 of 1,560

RecordTitlePhaseStatusStartPrimary completion
NCT07680790Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)Phase 3RecruitingSep 8, 2026Dec 30, 2031 (estimated)
NCT06976203A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Phase 3RecruitingJul 21, 2025Sep 11, 2028 (estimated)
NCT07355478Asia Myelodysplastic Syndrome (MDS) RegistryNot listedRecruitingAug 11, 2026Oct 31, 2026 (estimated)
NCT07011745A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease3RecruitingJul 16, 2025Nov 3, 2028 (estimated)
NCT06035497A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Phase 1/Phase 2Active, not recruitingNov 20, 2023Aug 11, 2026 (actual)
NCT07544628A Phase 1 Study of Navlimetostat Tablet Formulations1RecruitingApr 27, 2026Nov 2, 2026 (estimated)
NCT06976216A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseasePhase 3RecruitingJul 14, 2025Sep 11, 2028 (estimated)
NCT07492680A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)Phase 2RecruitingJul 27, 2026Aug 15, 2028 (estimated)
NCT00724334A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With MyelofibrosisPhase 1/Phase 2CompletedJul 31, 2008May 28, 2014 (actual)
NCT06997029A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors1RecruitingAug 1, 2025Dec 14, 2028 (estimated)
NCT07288567A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)Phase 3RecruitingJan 29, 2026Dec 18, 2029 (estimated)
NCT06869551A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisPhase 3RecruitingMar 13, 2025Mar 6, 2030 (estimated)
NCT07800897A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy ParticipantsPhase 1RecruitingAug 31, 2026Mar 25, 2027 (estimated)
NCT07680764A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 2RecruitingSep 10, 2026Sep 15, 2028 (estimated)
NCT07017699A Study to Assess Deucravacitinib Safety in PregnancyNot listedRecruitingMar 21, 2025Apr 1, 2028 (estimated)
NCT07465029A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in SpainNot listedActive, not recruitingFeb 2, 2026Apr 23, 2026 (actual)
NCT06952465A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With PsoriasisNot listedActive, not recruitingJan 24, 2025Nov 30, 2031 (estimated)
NCT07458542Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid LeukemiaNot listedCompletedDec 9, 2025Jan 9, 2026 (actual)
NCT07171983A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid ArthritisPhase 1RecruitingFeb 27, 2026Jun 28, 2027 (estimated)
NCT07852962Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants.Phase 1Not yet recruitingFeb 10, 2027Jul 18, 2027 (estimated)
NCT06698887A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in KoreaNot listedRecruitingSep 11, 2024Mar 27, 2031 (estimated)
NCT07571148Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT UsersNot listedCompletedJan 16, 2026Mar 25, 2026 (actual)
NCT07852884First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainNot listedActive, not recruitingJul 15, 2026Sep 1, 2026 (actual)
NCT06419634Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromePhase 1TerminatedMay 29, 2024Aug 28, 2026 (actual)
NCT07763418A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal FunctionPhase 1RecruitingSep 8, 2026Dec 14, 2026 (estimated)
NCT07599007Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene FusionNot listedNot yet recruitingOct 31, 2026Dec 30, 2027 (estimated)
NCT07361497A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)Phase 3RecruitingMar 16, 2026Sep 18, 2030 (estimated)
NCT07221149A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)Phase 2/Phase 3RecruitingMar 13, 2026Nov 8, 2030 (estimated)
NCT06372457COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)Not listedActive, not recruitingDec 1, 2023Sep 29, 2025 (actual)
NCT07101094Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)Not listedRecruitingSep 22, 2025Jan 31, 2029 (estimated)
NCT07107373A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the USNot listedActive, not recruitingDec 22, 2023Jul 26, 2024 (actual)
NCT06971185A Study to Evaluate Treatment Patterns and Effectiveness of LuspaterceptNot listedCompletedNov 22, 2024Aug 1, 2025 (actual)
NCT07361510A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)Phase 3RecruitingMar 12, 2026Oct 14, 2031 (estimated)
NCT07846059Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic CardiomyopathyNot listedNot yet recruitingSep 30, 2026Mar 31, 2027 (estimated)
NCT07285798A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum DisorderPhase 3Not yet recruitingOct 2, 2026Aug 6, 2029 (estimated)
NCT06937229A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Phase 3RecruitingDec 2, 2025Jun 22, 2029 (estimated)
NCT04908202A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic DrugsPhase 3Active, not recruitingJul 13, 2021Sep 5, 2024 (actual)
NCT06951711A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)Phase 3RecruitingJun 13, 2025Nov 2, 2026 (estimated)
NCT05552976A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)Phase 3Active, not recruitingJan 10, 2023Sep 28, 2026 (estimated)
NCT05076175A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative ColitisPhase 2/Phase 3RecruitingMay 30, 2022Jul 12, 2032 (estimated)
NCT07780383A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose AdministrationPhase 1RecruitingAug 21, 2026Jun 17, 2027 (estimated)
NCT06799286A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung CancerPhase 1CompletedMay 7, 2025Sep 9, 2026 (actual)
NCT03899155Pan Tumor Rollover StudyPhase 2RecruitingAug 9, 2019Aug 25, 2029 (estimated)
NCT07293351A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)Phase 1/Phase 2RecruitingMar 26, 2026Nov 28, 2029 (estimated)
NCT07063745A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionPhase 2/Phase 3RecruitingJan 2, 2026Aug 12, 2031 (estimated)
NCT07221357A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal CancerPhase 2/Phase 3RecruitingDec 31, 2025Feb 2, 2030 (estimated)
NCT06618287A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsPhase 1/Phase 2RecruitingFeb 4, 2025Feb 26, 2031 (estimated)
NCT07291076A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Phase 1/Phase 2RecruitingMar 16, 2026Oct 15, 2029 (estimated)
NCT06561386A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%Phase 3RecruitingOct 7, 2024Jul 30, 2030 (estimated)
NCT07100080Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)Phase 2/Phase 3RecruitingNov 5, 2025Dec 15, 2028 (estimated)

FDA records (last 2 years)

Connect

See your connections at Bristol-Myers Squibb on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback